Global phase III trials demonstrate that nerandomilast slowed lung function decline in IPF and PPF, with similar discontinuation ...
Boehringer Ingelheim announced today detailed findings from the Phase III FIBRONEER™-IPF and FIBRONEER™-ILD trials. These studies evaluated nerandomilast, an investigational oral, preferential inhibitor of phosphodiesterase 4B (PDE4B), in patients with …